Big Pharma Eyes Cannabis as Schedule III Move Draws New Investment

Major pharmaceutical companies are exploring opportunities in the cannabis industry as federal rescheduling moves forward, signaling a potential shift in corporate America's approach to marijuana business.

The Drug Enforcement Administration's proposal to move cannabis from Schedule I to Schedule III has prompted pharmaceutical firms and institutional investors to reconsider their stance on the sector. Companies that previously avoided marijuana due to its federal illegal status are now conducting due diligence on potential investments and partnerships.

The rescheduling proposal, currently under review at the White House Office of Management and Budget, would reclassify cannabis alongside drugs like ketamine and testosterone. While marijuana would remain federally controlled, the change removes it from the same category as heroin and LSD—a distinction that matters significantly to risk-averse pharmaceutical companies and their investors.

Wall Street Warming Up

Financial institutions that stayed on the sidelines during cannabis's early growth years are reassessing their positions. The stigma that kept major banks and investment firms away is eroding as rescheduling gains momentum through the federal regulatory process.

Pharmaceutical interest centers on several factors beyond just the regulatory shift. The industry sees potential in developing FDA-approved cannabis-derived medications, expanding beyond the limited cannabinoid drugs currently on the market. Epidiolex, the only FDA-approved CBD medication, generated hundreds of millions in annual sales, demonstrating market demand for regulated cannabis therapeutics.

But the pharmaceutical sector's entry could reshape the cannabis landscape in ways the existing industry might not welcome. Large drug companies bring extensive regulatory expertise and deep pockets—advantages that could help them dominate medical cannabis markets while potentially marginalizing smaller operators.

The Tax Question

Rescheduling would eliminate Section 280E of the tax code for cannabis businesses, allowing standard business deductions currently prohibited for Schedule I substances. This change alone could improve profit margins by 30-40% for many operators, making the sector substantially more attractive to traditional investors focused on bottom-line performance.

Pharmaceutical companies are particularly interested in this tax benefit combined with their existing infrastructure for clinical trials and FDA approval processes. They could leverage rescheduling to fast-track cannabis-based drug development while operating under familiar regulatory frameworks.

The timing aligns with growing clinical evidence supporting cannabis applications for conditions ranging from chronic pain to PTSD. Pharmaceutical firms see an opportunity to medicalize cannabis through their traditional development pathways, potentially creating prescription products that compete with dispensary sales.

What Happens Next

The rescheduling process faces an uncertain timeline. After OMB review, the DEA must publish a final rule and address public comments—a process that could extend into 2025 or beyond. Legal challenges from prohibition advocates could further delay implementation.

Meanwhile, pharmaceutical companies are positioning themselves through preliminary research partnerships and market analysis. Some are quietly hiring cannabis industry veterans as consultants, building knowledge bases for potential future entry.

The cannabis industry's reaction remains mixed. While rescheduling brings legitimacy and capital, it also invites competition from companies with vastly superior resources. Small and mid-sized operators worry about maintaining market share once pharmaceutical giants enter the space with branded medications and massive marketing budgets.

Investors watching the sector should note that pharmaceutical interest doesn't guarantee immediate deals. These companies move deliberately, waiting for regulatory certainty before committing significant capital. But their growing attention signals a fundamental shift in how corporate America views cannabis—from untouchable to investable.

---

This article is based on original reporting by mjbizdaily.com.